Protection of taraxasterol against acetaminophen-induced liver injury elucidated through network pharmacology and in vitro and in vivo experiments

• Published in: Phytomedicine (Stuttgart) Vol. 116; p. 154872
• Main Authors: Ge, Bingjie, Sang, Rui, Wang, Wei, Yan, Kexin, Yu, Yifan, Kong, Lin, Yu, Minghong, Liu, Xinman, Zhang, Xuemei
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 25.07.2023
• Subjects: Acetaminophen; Acetaminophen - adverse effects; AML12 cells; Animals; Chemical and Drug Induced Liver Injury - metabolism; Chemical and Drug Induced Liver Injury, Chronic - metabolism; Liver; Liver injury; Mice; Network Pharmacology; NF-E2-Related Factor 2 - metabolism; Oxidative Stress; Taraxasterol; Triterpenes - metabolism; Triterpenes - pharmacology; JNK; ALT; ITS; HO-1; MDA; TUNEL; bw; Nrf2; FBS; KEGG; Network pharmacology; GSH; RT-qPCR; Bif; AST; GO; DAPI; SOD; IL-1β; PVDF; IL-6; Liver injury; ECL; SDS-PAGE; TNF-α; Acetaminophen; TTBS; DMEM/F-12; ROS; Sil; AML12 cells; Mice; Taraxasterol; HE; TEM
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2023.154872

: Drug-induced liver injury (DILI) is primarily caused by drugs or their metabolites. Acetaminophen (APAP) is an over-the-counter antipyretic analgesic that exhibits high hepatotoxicity when used for long-term or in overdoses. Taraxasterol is a five-ring triterpenoid compound extracted from traditional Chinese medicinal herb Taraxacum officinale. Our previous studies have demonstrated that taraxasterol exerts protective effects on alcoholic and immune liver injuries. However, the effect of taraxasterol on DILI remains unclear. : This study aimed to elucidate the effects and mechanisms of action of taraxasterol on APAP-induced liver injury using network pharmacology and in vitro and in vivo experiments. : Online databases of drug and disease targets were used to screen the targets of taraxasterol and DILI, and a protein-protein interaction network (PPI) was constructed. Core target genes were identified using the tool of Analyze of Cytoscape, gene ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) enrichment analyses were performed. Oxidation, inflammation and apoptosis were evaluated to determine the effect of taraxasterol on APAP-stimulated liver damage in AML12 cells and mice. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting were used to explore the potential mechanisms of taraxasterol against DILI. : Twenty-four intersection targets for taraxasterol and DILI were identified. Among them, 9 core targets were identified. GO and KEGG analysis showed that core targets are closely related to oxidative stress, apoptosis, and inflammatory response. The in vitro findings showed that taraxasterol alleviated mitochondrial damage in AML12 cells treated with APAP. The in vivo results revealed that taraxasterol alleviated pathological changes in the livers of mice treated with APAP and inhibited the activity of serum transaminases. Taraxasterol increased the activity of antioxidants, inhibited the production of peroxides, and reduced inflammatory response and apoptosis in vitro and in vivo. Taraxasterol promoted Nrf2 and HO-1 expression, suppressed JNK phosphorylation, and decreased the Bax/Bcl-2 ratio and caspase-3 expression in AML12 cells and mice. : By integrating network pharmacology with in vitro and in vivo experiments, this study indicated that taraxasterol inhibits APAP-stimulated oxidative stress, inflammatory response and apoptosis in AML12 cells and mice by regulating the Nrf2/HO-1 pathway, JNK phosphorylation, and apoptosis-related protein expression. This study provides a new evidence for the use of taraxasterol as a hepatoprotective drug. [Display omitted]